Indeed, we found that overexpression of the newly characterized SWIFT domain attenuated the proliferation of several TF-addicted cancer cell lines to comparable degrees as treatment with FHD-286, a clinical-grade dual SMARCA4/2 ATPase inhibitor that recently was evaluated in Phase I studies (Fig. 5F, S8G). The gene discussed is SMARCA4; the disease is cancer.